FLJ22184 Activators
FLJ22184 Activators encompass a variety of chemical compounds that indirectly amplify the functional activity of FLJ22184 by modulating distinct cellular signaling pathways. For instance, Forskolin, by increasing cAMP levels, activates PKA, which could phosphorylate FLJ22184, should it be susceptible to cAMP-dependent phosphorylation. Similarly, the kinase inhibitor EGCG could disarm regulatory kinases that compete with or inhibit FLJ22184's activity, thereby facilitating its function. Phorbol ester PMA, a PKC activator, and Ionomycin, a calcium ionophore, may each lead to phosphorylation events that activate.
Proteasome Activators are a select group of compounds that augment the activity of the Proteasome through various mechanisms within the cell's biochemical milieu. Compounds such as MG-132 and Bortezomib primarily function by inhibiting the proteasome's ability to degrade ubiquitinated proteins, resulting in an adaptive increase in Proteasome activity to counteract the inhibition. This indirect method of activation ensures that the cell maintains protein homeostasis. Similarly, natural compounds like Betulinic acid and Withaferin A modulate Proteasome activity by either stabilizing its active configuration or inducing stress responses that upregulate the Proteasome's functionality. Disulfiram's enhancement of the Proteasome's chymotrypsin-like activity
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing intracellular cAMP levels. This, in turn, activates PKA which could phosphorylate FLJ22184, enhancing its functional activity if it is regulated by cAMP-dependent phosphorylation. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor that may enhance FLJ22184 function by inhibiting competitive kinase pathways, thus potentially freeing FLJ22184 from inhibitory phosphorylation and increasing its activity if it is regulated by such kinases. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which could lead to the phosphorylation and activation of FLJ22184 if it is a substrate for PKC or part of a pathway regulated by PKC. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin increases intracellular calcium levels, which may activate calcium-dependent kinases that phosphorylate and activate FLJ22184 if it is regulated by calcium-dependent signaling. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate acts via G protein-coupled receptors to activate downstream kinases, potentially leading to the activation of FLJ22184 if it is involved in such signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, which could enhance FLJ22184 function by altering the phosphorylation state if FLJ22184 is regulated by PI3/Akt signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAPK, which could lead to the activation of FLJ22184 if it is negatively regulated by p38 MAPK signaling. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that could enhance FLJ22184 activity by inhibiting upstream tyrosine kinases that negatively regulate FLJ22184 if it is part of tyrosine kinase signaling pathways. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin disrupts calcium homeostasis, which could activate FLJ22184 if it is regulated by calcium-dependent signaling pathways, by increasing intracellular calcium levels. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor that might enhance FLJ22184 activity by selectively inhibiting kinases that negatively regulate FLJ22184. | ||||||